Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

colorectal cancer

This page shows the latest colorectal cancer news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AstraZeneca’s PD-L1 inhibitor Imfinzi and Bavarian Nordic’s cancer vaccine CV301 will be combined in a phase I/II trial involving patients with metastatic colorectal or pancreatic cancers. ... Colorectal and pancreatic cancers are among the most

Latest news

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    market. Growth has also come from a steady stream of new indications, including recent approvals in hepatocellular carcinoma, renal cell carcinoma and colorectal cancer. ... stable trends”in second-line lung cancer in the US and good growth elsewhere

  • Prospects for Lilly’s Verzenio hit by botched lung cancer trial Prospects for Lilly’s Verzenio hit by botched lung cancer trial

    it has “several studies ongoing of rational combinations that include abemaciclib in non-small cell lung cancer and other malignancies”. ... It is nevertheless a setback to Lilly’s plans to develop the drug for specific tumour mutations such as KRAS

  • Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

    Germany and the UK will be the first to receive the skin cancer treatment. ... it introduced colorectal and head and neck cancer therapy Erbitux (cetuximab) more than a decade ago.

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    The green light is a big boost for the product which has been wrestling with tough competition in one of its other approved indications - colorectal cancer and gastrointestinal stromal tumours (GIST) - ... Meanwhile Bayer is also carrying out studies

  • Keytruda is first FDA-approved drug for molecular indication Keytruda is first FDA-approved drug for molecular indication

    The cancer drug has become the first to be approved by the FDA to treat all cancers with a specific tumour biomarker. ... BMS reported data last year showing that Opdivo was also effective in MSI-H colorectal cancer, both alone and in combination with

More from news
Approximately 18 fully matching, plus 225 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.

  • Winning the war against cancer Winning the war against cancer

    data sources and the organisation of screening programmes for colorectal cancer. ... Cancer is an important disease to see [its] impact on the health system.

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to

  • Pharma deals during February 2014 Pharma deals during February 2014

    MK-3475 was awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. ... BATON studies in colorectal cancer and metastatic triple negative breast cancer.

  • The oncology market in Canada The oncology market in Canada

    on the other side of the border, three tumours have comparable incidence rates, while colorectal cancer is a distant number four. ... Colorectal cancer. Colorectal cancer is where the two countries demonstrate the most substantial differences.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Lynch syndrome: a patient perspective

    My grandfather was probably the first in the family to be afflicted with Lynch syndrome or Hereditary Nonpolyposis Colorectal Cancer (HNPCC). ... A revolutionary discovery. For my father, the cancer came back four more times.

  • 90TEN nominated for five Communiqué Awards

    Meanwhile two of the agency’ s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Quick links

Infographics

Multimedia